多区域免疫谱分析揭示膀胱癌预后模式
本研究纳入251例接受膀胱切除术的肌层浸润性膀胱癌患者,从肿瘤浸润前沿和中心取样,定量检测六种免疫检查点蛋白。基于免疫检查点蛋白的聚类识别出三种肿瘤免疫微环境亚型,其中CID3亚型预后显著更差(中位总生存期18.5 vs 100.5个月;p=0.0007),该分类优于UICC分期。
要点
- 六种免疫检查点蛋白面板可实现不依赖分期的风险分层。
- CID3亚型与显著更差预后相关,中位OS 18.5 vs 100.5个月。
- 常规免疫谱分析建议至少取4个活检样本。
核心结论
- 六种免疫检查点蛋白的多区域面板可在肌层浸润性膀胱癌中提供稳健、不依赖分期的风险分层。
研究设计与样本
- 研究纳入251例2004-2014年在LMU Munich接受膀胱切除术的肌层浸润性膀胱癌患者。
- 从肿瘤浸润前沿和中心各取三个直径1毫米的组织芯,进行免疫组化染色和数字化定量。
主要发现
- IDO+和VISTA+免疫细胞在肿瘤免疫微环境中占主导,PD-L1+肿瘤细胞呈双相表达模式。
- 三个空间不同组织芯足以恢复低丰度TIM-3+和VISTA+免疫细胞的最大表达,其他标志物需四个组织芯。
- 基于免疫检查点蛋白的聚类识别出三种肿瘤免疫微环境亚型(CID1-3),CID3与显著更差预后相关(中位OS 18.5 vs 100.5个月;p=0.0007)。
- 该分类优于UICC分期,并改善晚期肌层浸润性膀胱癌患者的分层。
关键数值与推荐
- CID3亚型中位总生存期为18.5个月,对比其他亚型100.5个月(p=0.0007)。
- 常规免疫谱分析建议至少取4个活检样本。
临床怎么用
- 可采用六种免疫检查点蛋白面板对肌层浸润性膀胱癌进行风险分层,辅助识别高危患者。
- 取样时建议至少4个活检样本以确保可靠免疫谱分析。
局限性
- 需要进一步纵向外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Muscle-invasive bladder cancer (MIBC) is a biologically heterogeneous disease with variable prognosis after radical cystectomy. While conventional clinicopathological parameters offer limited prognostic value, growing evidence highlights the role of the tumor immune microenvironment (TIME)-including immune cell composition and spatial architecture-as robust biomarkers for disease progression and outcomes. METHODS: The study included 251 consecutive patients with MIBC who underwent cystectomy (2004-2014, LMU Munich). Three 1-mm-diameter cores were sampled from the tumor invasive front and center in the cystectomy specimen. Six immune checkpoint proteins (ICPs; IDO, PD-L1, PD-1, LAG-3, TIM-3, and VISTA) were quantified digitally following immunohistochemical (IHC) staining. ICP-positive immune and tumor cells were stratified and densities were hierarchically clustered. Multivariable Cox models were then used to assess the association with overall (OS) and disease-free survival. The minimum tumor sample count needed to detect the maximum ICP expression per patient was estimated via a 1000-fold bootstrap resampling simulation. KEY FINDINGS AND LIMITATIONS: IDO+ and VISTA+ immune cells dominated the TIME, while PD-L1+ tumor cells exhibited a dichotomous expression pattern. Analysis of three spatially distinct cores was sufficient to recover maximal expression of low-abundance TIM-3+ and VISTA+ immune cells, while four cores were required for all other markers. ICP-based clustering revealed three TIME subtypes (CID1-3), of which CID3 was associated with markedly worse prognosis (median OS 18.5 vs 100.5 mo; p = 0.0007). This classification outperformed Union for International Cancer Control staging and improved patient stratification in late-stage MIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: A six-marker, multiregional ICP panel delivers a robust, stage-independent, actionable risk stratification in MIBC. At least four biopsies are advised for routine immune profiling; further longitudinal external validation is warranted.
引用
- Jurczok N, Dernbach G, Ebner B, et al. Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer. Eur Urol Oncol. 2025. PMID: 41475987. doi:10.1016/j.euo.2025.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。